Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Fig. 1

Genetic variants of the PI3K pathway genes. DNA extracted from NZM cell lines was subjected to whole-exome sequencing. The top row indicates the number of variants per cell line for the genes included. Middle rows indicate colour-coded individual variants found in 52 NZM cell lines. Side panels indicate the percentage of cell lines with mutations per gene. The bottom row indicates cell line names

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us